August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
Pension Savings Rules Get a Reset as the EU Scraps the 1% CapMedicine Shortages Move to the Heart of Europe’s Pharma ResetJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayPension Savings Rules Get a Reset as the EU Scraps the 1% CapMedicine Shortages Move to the Heart of Europe’s Pharma ResetJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips Away
August 9, 2026

Newsletter

The European Post

Policy • Diplomacy • Strategic Insight

LATEST
Pension Savings Rules Get a Reset as the EU Scraps the 1% CapMedicine Shortages Move to the Heart of Europe’s Pharma ResetJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips AwayPension Savings Rules Get a Reset as the EU Scraps the 1% CapMedicine Shortages Move to the Heart of Europe’s Pharma ResetJapan Becomes Europe’s Closest Security Partner in AsiaCan Europe’s New Zealand Deal Anchor It in the Pacific?Chip Research Binds Europe and South Korea CloserMinimum Prices Replace Tariffs in Europe’s China Car DealBrussels and Beijing Keep Talking While the Trade Gap WidensKorean Weapons and EU Loans Now Bankroll Europe’s RearmamentNew EU Gas Market Rules Take Effect With Consumer SafeguardsDeforestation Regulation Holds Its December Deadline Despite CutsDigital Omnibus Delays Europe’s High-Risk AI Deadline to 2027Europe’s Schools Confront a Widening Basic Skills GapRule of Law Report Finds Progress but Trust Still LagsIRIS2 Gains 66 Satellites as Brussels Signs the Rollout DealNature Restoration Plans Come Due as Member States Race a DeadlineECB Rates Hold at 2.25 Percent as Frankfurt Waits on the DataEU Budget Talks Turn to Cohesion as Ireland Takes OverWildfire Response Stretches Europe’s Emergency Fleet ThinCan Europe’s Quantum Plan Match Its Big Ambitions?Armenia Edges West as Moscow’s Grip Slips Away

Parkinson’s and Diabetes Patients Gain Newly Backed Medicines

Jóhannes Guðnason
Legislative Affairs Editor, Health and Wellbeing

Munich: Europe’s drug regulator has cleared a fresh batch of new medicines for the market, and the list reaches patients who often wait longest for better options. At its June meeting, the human medicines committee of the European Medicines Agency recommended six treatments for approval and backed wider use for eleven products already on pharmacy shelves.

Two of the newcomers stand out. The committee endorsed a levodopa and carbidopa combination for adults with Parkinson’s disease who suffer moderate-to-severe swings in their motor control, the difficult periods when medication wears off and movement stiffens. Neurologists have long asked for smoother ways to manage those fluctuations, and the recommendation gives them another tool.

The committee also backed a once-weekly insulin for adults with type 2 diabetes. A single weekly injection could ease the daily burden that pushes many patients to skip doses, and doctors hope the simpler routine will help people hold their blood sugar steady over the long haul.

Vaccines featured heavily as well. The committee recommended lowering the approved age for a smallpox and mpox vaccine so that children from two years old can receive it, a change that matters for families in regions where mpox still circulates. It also cleared an influenza vaccine aimed at older adults, part of a steady effort to shield Europe’s ageing population before each winter season.

The eleven expanded approvals rarely grab headlines, yet they shape everyday care. The committee extended existing cancer, immunology and HIV therapies to new groups of patients, which lets physicians prescribe familiar drugs for a wider set of conditions without waiting for entirely fresh applications.

Each recommendation now travels to the European Commission, which issues the formal marketing authorisation that clears a medicine for all 27 member states. That step usually follows within weeks, and national health systems then decide how to price and reimburse the products, the stage where access often stalls despite a green light from the regulator.

The agency frames its monthly verdicts as the quiet engine of European health policy. Companies apply once, a single committee assesses the evidence, and a positive opinion opens an entire continent rather than one national market. That pooled approach gives smaller countries the same early access as the largest, and it spreads the cost of rigorous review across the whole Union.

Patient groups welcomed the batch but repeated their familiar warning. A recommendation in June means little to a Parkinson’s patient in a country that will not fund the drug until next year, and the gap between approval and access remains the sharpest complaint in European medicine. The full rundown of the June opinions sits on the agency’s meeting highlights page for anyone who wants the clinical detail.

Comments